SEP-225289 serotonin and dopamine transporter occupancy: A PET study

Journal of Nuclear Medicine

Volumn 52, Issue 7, 2011, Pages 1150-1155

  DeLorenzo, Christine ^a   Lichenstein, Sarah ^b   Schaefer, Karen ^b   Dunn, Judith ^c   Marshall, Randall ^d   Organisak, Lisa ^d   Kharidia, Jahnavi ^d   Robertson, Brigitte ^d   Mann, J John ^a,b   Parsey, Ramin V ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Dopamine; Occupancy; Positron emission tomography; SEP 225289; Serotonin

Indexed keywords

1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; DOPAMINE TRANSPORTER; N (3 IODOPROP 2 ENYL) 2BETA CARBOMETHOXY 3BETA (4 METHYLPHENYL)NORTROPANE C 11; N,N DIMETHYL 2 (2 AMINO 4 CYANOPHENYLTHIO)BENZYLAMINE C 11; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; CAUDATE NUCLEUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; IC 50; INSOMNIA; MALE; MESENCEPHALON; NAUSEA; NEUROIMAGING; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; AMINES; COHORT STUDIES; CYCLOBUTANES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN TRANSPORT; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 79960297171     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.084525     Document Type: Article

References (29)

1. Leuchter AF, Lesser IM, Trivedi MH, et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatr Pract. 2008;14:271-280.
2. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol. 2008;23:113-119. (Pubitemid 351535902)
3. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-1252.
4. Chen Z, Skolnick P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs. 2007;16:1365-1377. (Pubitemid 47491407)
5. McMillen BA, Shank JE, Jordan KB, Williams HL, Basile AS. Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat. Alcohol Clin Exp Res. 2007;31:1866-1871. (Pubitemid 47609650)
6. Ross S, Peselow E. Pharmacotherapy of addictive disorders. Clin Neuropharmacol. 2009;32:277-289.
7. Castells X, Casas M, Perez-Mana C, Roncero C, Vidal X, Capella D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2010;2:CD007380.
8. Mease PJ. Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. Am J Med. 2009;122:S44-S55.
9. Basile AS, Janowsky A, Golembiowska K, et al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther. 2007;321:1208-1225. (Pubitemid 46762716)
10. Tizzano JP, Stribling DS, Perez-Tilve D, et al. The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. J Pharmacol Exp Ther. 2008;324:1111-1126.
11. Steffen KJ, Roerig JL, Mitchell JE, Uppala S. Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006;11:315-336. (Pubitemid 43723311)
12. Schreiber R, Lew R, Hardy L, Cremers T, Fang QK, Campbell U. (2009). Pharmacological characterization of the triple monoamine transporter inhibitor SEP-225289. Paper presented at: Meeting of Society for Neuroscience; October 20, 2009; Chicago, IL.
13. 11C]raclopride. J Psychopharmacol. 2002;16:195-199.
14. 11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826-835.
15. 2A receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 2007;190:241-249.
16. Uppoor RS, Mummaneni P, Cooper E, et al. The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs. Clin Pharmacol Ther. 2008;84:69-74. (Pubitemid 351861484)
17. Grimwood S, Hartig PR. Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol Ther. 2009;122:281-301.
18. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl). 2002;163:102-105. (Pubitemid 34985318)
19. 1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007;164:1411-1417.
20. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry. 1995;152:1444-1449.
21. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293. (Pubitemid 29077120)
22. 11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Psychiatry Res. 1998;82:147-160.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
24. DeLorenzo C, Kumar JSD, Zanderigo F, Mann JJ, Parsey RV. Modeling considerations for in vivo quantification of the dopamine transporter using [C-11]PE2I and positron emission tomography. J Cereb Blood Flow Metab. 2009;29:1332-1345.
25. 11C]DASB and positron emission tomography in humans: modeling considerations. J Cereb Blood Flow Metab. 2007;27:205-217.
26. 11C-CUMI-101, an agonist PET radiotracer. J Nucl Med. 2010;51:1892-1900.
27. DeLorenzo C, Klein A, Mikhno A, et al. A new method for assessing PET-MRI coregistration. In: SPIE Medical Imaging. Bellingham, WA: SPIE; 2009:72592W-72598.
28. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539. (Pubitemid 47301451)
29. 3H]-N-(2-(4-(2-methoxyphenyl)-1- piperazinyl)ethyl)-N-(2-py ridinyl) cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther. 2002;301:1144-1150.